Cargando…

Development of cancer genetic services in the UK: A national consultation

BACKGROUND: Technological advances in DNA sequencing have made gene testing fast and affordable, but there are challenges to the translation of these improvements for patient benefit. The Mainstreaming Cancer Genetics (MCG) programme is exploiting advances in DNA sequencing to develop the infrastruc...

Descripción completa

Detalles Bibliográficos
Autores principales: Slade, Ingrid, Riddell, Daniel, Turnbull, Clare, Hanson, Helen, Rahman, Nazneen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341881/
https://www.ncbi.nlm.nih.gov/pubmed/25722743
http://dx.doi.org/10.1186/s13073-015-0128-4
_version_ 1782359218633834496
author Slade, Ingrid
Riddell, Daniel
Turnbull, Clare
Hanson, Helen
Rahman, Nazneen
author_facet Slade, Ingrid
Riddell, Daniel
Turnbull, Clare
Hanson, Helen
Rahman, Nazneen
author_sort Slade, Ingrid
collection PubMed
description BACKGROUND: Technological advances in DNA sequencing have made gene testing fast and affordable, but there are challenges to the translation of these improvements for patient benefit. The Mainstreaming Cancer Genetics (MCG) programme is exploiting advances in DNA sequencing to develop the infrastructure, processes and capabilities required for cancer gene testing to become routinely available to all those that can benefit. METHODS: The MCG programme held a consultation day to discuss the development of cancer genetics with senior representation from all 24 UK cancer genetic centres. The current service landscape and capacity for expansion was assessed through structured questionnaires. Workshop discussion addressed the opportunities and challenges to increasing cancer gene testing in the National Health Service (NHS). RESULTS: Services vary with respect to population served and models of service delivery, and with respect to methods and thresholds for determining risk and testing eligibility. Almost all centres want to offer more cancer gene testing (82%) and reported increasing demand for testing from non-genetic clinical colleagues (92%). Reported challenges to increasing testing include the complexity of interpreting the resulting genetic data (79%), the level of funding and complexity of commissioning (67%), the limited capacity of current processes and cross-disciplinary relationships (38%), and workforce education (29%). CONCLUSIONS: Priorities to address include the development and evaluation of models of increasing access to gene testing, the optimal process for interpretation of large-scale genetic data, implementation of appropriate commissioning and funding processes, and achieving national consistency. The UK cancer genetics community have high expertise and strong commitment to maximising scientific advances for improved patient benefit and should be pivotally involved in the implementation of increased cancer gene testing. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-015-0128-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4341881
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43418812015-02-27 Development of cancer genetic services in the UK: A national consultation Slade, Ingrid Riddell, Daniel Turnbull, Clare Hanson, Helen Rahman, Nazneen Genome Med Research BACKGROUND: Technological advances in DNA sequencing have made gene testing fast and affordable, but there are challenges to the translation of these improvements for patient benefit. The Mainstreaming Cancer Genetics (MCG) programme is exploiting advances in DNA sequencing to develop the infrastructure, processes and capabilities required for cancer gene testing to become routinely available to all those that can benefit. METHODS: The MCG programme held a consultation day to discuss the development of cancer genetics with senior representation from all 24 UK cancer genetic centres. The current service landscape and capacity for expansion was assessed through structured questionnaires. Workshop discussion addressed the opportunities and challenges to increasing cancer gene testing in the National Health Service (NHS). RESULTS: Services vary with respect to population served and models of service delivery, and with respect to methods and thresholds for determining risk and testing eligibility. Almost all centres want to offer more cancer gene testing (82%) and reported increasing demand for testing from non-genetic clinical colleagues (92%). Reported challenges to increasing testing include the complexity of interpreting the resulting genetic data (79%), the level of funding and complexity of commissioning (67%), the limited capacity of current processes and cross-disciplinary relationships (38%), and workforce education (29%). CONCLUSIONS: Priorities to address include the development and evaluation of models of increasing access to gene testing, the optimal process for interpretation of large-scale genetic data, implementation of appropriate commissioning and funding processes, and achieving national consistency. The UK cancer genetics community have high expertise and strong commitment to maximising scientific advances for improved patient benefit and should be pivotally involved in the implementation of increased cancer gene testing. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-015-0128-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-02-02 /pmc/articles/PMC4341881/ /pubmed/25722743 http://dx.doi.org/10.1186/s13073-015-0128-4 Text en © Slade et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Slade, Ingrid
Riddell, Daniel
Turnbull, Clare
Hanson, Helen
Rahman, Nazneen
Development of cancer genetic services in the UK: A national consultation
title Development of cancer genetic services in the UK: A national consultation
title_full Development of cancer genetic services in the UK: A national consultation
title_fullStr Development of cancer genetic services in the UK: A national consultation
title_full_unstemmed Development of cancer genetic services in the UK: A national consultation
title_short Development of cancer genetic services in the UK: A national consultation
title_sort development of cancer genetic services in the uk: a national consultation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341881/
https://www.ncbi.nlm.nih.gov/pubmed/25722743
http://dx.doi.org/10.1186/s13073-015-0128-4
work_keys_str_mv AT sladeingrid developmentofcancergeneticservicesintheukanationalconsultation
AT riddelldaniel developmentofcancergeneticservicesintheukanationalconsultation
AT turnbullclare developmentofcancergeneticservicesintheukanationalconsultation
AT hansonhelen developmentofcancergeneticservicesintheukanationalconsultation
AT rahmannazneen developmentofcancergeneticservicesintheukanationalconsultation
AT developmentofcancergeneticservicesintheukanationalconsultation